In situ rifampin-soaked grafts with omental coverage and antibiotic suppression are durable with low reinfection rates in patients with aortic graft enteric erosion or fistula  by Oderich, Gustavo S. et al.
From the Society for Vascular Surgery
In situ rifampin-soaked grafts with omental
coverage and antibiotic suppression are durable
with low reinfection rates in patients with aortic
graft enteric erosion or fistula
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Audra A. Duncan, MD,a John W. Wilson, MD,b Stephan Cha, MS,c and
Peter Gloviczki, MD,a Rochester, Minn
Objective:We previously reported that in situ rifampin-soaked grafts (ISRGs) were safe in select patients with aortic graft
infections, with the best results in those with aortic graft enteric erosion or fistula (AGEF). This study evaluates the late
results of ISRG for AGEF.
Methods: From 1990 to 2008, 183 patients were treated for aortic graft infections (121 primary and 62 AGEF). We
reviewed 54 patients treated for AGEF with a standard protocol, which included excision of the infected part of the graft,
intestinal repair, ISRG with omental wrap, and long-term antibiotics. We excluded 8 patients with AGEF (13%) treated
with axillofemoral grafts (AXFG, n  5) or in situ femoral vein (n  3) due to excessive perigraft purulence. Endpoints
were early morbidity and mortality, late survival, reinfection, and graft-related complications.
Results: There were 45 male patients and 9 female patients with a mean age of 69  9 years. Presentation was
gastrointestinal bleeding in 33 patients, fever in 25 patients, and hemorrhagic shock in 10 patients. Other features were
perigraft fluid in 29 patients and purulence in 9 patients. Forty-two patients (80%) had infections isolated to a portion of the
graft body or limb, with the remainder of the graft well incorporated. Total graft excision was performed in 31 patients and
partial excision in 23 patients. Total operating time was 6.2 1.9 hours. Postoperative complications occurred in 28 patients
(52%), and there were 5 deaths (9%). Operative mortality was 2.3% in stable patients (1 of 44) and 40% in those with
hemorrhagic shock (4 of 10; P < .001). The hospital stay was 20  18 days. Mean follow-up was 51 months (range, 3-197
months). Five-year patient survival, primary graft patency, and limb salvage rates were 59  8%, 92  5%, and 100%,
respectively. There were no late graft-related deaths. There were two (4%) graft reinfections, one that was treated with
axillofemoral bypass, and the other with perigraft fluid aspiration and oral antibiotic suppression.
Conclusion: ISRGs with omental wrap and long-term antibiotics are associated with low reinfection rates in patients with
AGEF who do not have excessive perigraft purulence. Graft patency and limb salvage rates are excellent. ( J Vasc Surg
2011;53:99-107.)Aortic graft enteric erosion or fistula (AGEF) is a life-
threatening complication that occurs in 1% to 2% of abdomi-
nal aortic reconstructions.1 Factors that affect outcome in-
clude multiple patient comorbidities, hemorrhagic shock,
sepsis, and involvement of the visceral arteries. Axillofemoral
bypass (AXFB) through a noninfected field has been associ-
ated withmortality of 11% to 27%, amputation in 11% to 16%
of patients, aortic stump blowout in 3% to 20%, and graft
reinfection in 3% to 15%.2-4 In addition, AXFB requires pro-
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doi:10.1016/j.jvs.2010.08.018longed lower extremity ischemia in patients who cannot wait
for staged procedures because of gastrointestinal bleeding,
and closure of the aortic stump may be difficult if the aortic
anastomosis abuts the renal arteries.
In situ replacement using the femoropopliteal vein, cryo-
preserved arterial allograft, or prosthetic graft avoids some of
the challenges described above. The ideal conduit remains
controversial, but each has its disadvantages. Femoral vein
harvest adds to the already long operative time and is associ-
ated with graft-related hemorrhage in 5% of patients, major
amputation in 5% to 10%, the need for fasciotomy in 20%, and
chronic leg edema in 30%.5-9 Cryopreserved arterial allografts
may not be available at all centers, are costly ($18,000 US
dollars per aortoiliac segment) and carry a risk of blowout in
3% to 9% of patients.10-13 Prosthetic grafts are readily avail-
able, but their use has faced skepticismbecause of the potential
risk for graft reinfection.14-20 In a previous report of aortic
graft infections, the lowest rates of reinfection occurred
among patients treated for AGEF (3%) compared to primary
graft infection (23%).20 The purpose of this study was to
evaluate the results of in situ rifampin-soaked grafts (ISRGs)
for AGEF.
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This study was approved by the Institutional Review
Board of the Mayo Clinic. One hundred eighty-three pa-
tients were treated for aortic graft infections between 1990
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femoral vein grafts (n  3) because of a large abscess or
excessive purulence (Fig 2, online only).
Medical records were reviewed for patient demograph-
ics, clinical characteristics, radiologic, microbiologic, and
operative data. The presence of perigraft abscess or puru-
lence was determined by review of preoperative imaging,
operative reports, and intraoperative photographs when
available. Aortic graft fistula was defined by involvement of
the anastomotic suture line and erosion by para-prosthetic
involvement, which did not affect the anastomotic line.
Hemorrhagic shock was defined as massive bleeding with
systolic blood pressures of 80 mm Hg requiring fluid
resuscitation and/or vasopressors. All patients with massive
bleeding had aortic graft enteric fistulas. Normal serum
creatinine was defined as 1.5 mg/dL and renal insuffi-
ciency as a rise in serum creatinine by0.5 mg/dL. Graft-
related complications were procedure-related death, re-
intervention, graft re-infection, stenosis/thrombosis,
anastomotic aneurysm, or limb loss. Late follow-up was
obtained from medical records, correspondence with refer-
ring physicians, telephone interviews, and from a detailed
questionnaire. Late mortality data were obtained from the
National Death Index Search if needed.
Technique of ISRG replacement. ISRG replacement
was used in the absence of a large abscess or excessive
purulence. The operation was performed through a mid-
line, transperitoneal approach. Control was obtained of the
infrarenal aorta, except for patients with supra-graft aneu-
rysms, aortic anastomosis close to the renal arteries, or
perirenal inflammation or scar, which necessitated a higher
clamp position. Whenever possible, we avoided entering
the enteric communication during the dissection and left a
“patch” of the old graft attached to the intestine to avoid
spillage of enteric content (Fig 3, online only). The infected
graft was excised, but portions of the graft limbs were
preserved if well incorporated. The infected graft was sent
for immediate gram stain and aerobic, anaerobic, and fun-
gal cultures. After retroperitoneal debridement and irriga-
tion, instruments, gowns, and gloves were changed. The
aorta was replaced using a polyester graft presoaked in 600
mg Rifampin powder solution (Merrell Dow Pharmaceuti-
cal, Kansas City, Mo) diluted in 250 mL of normal saline
(2.4mg/mL) for at least 30minutes. The limbs of this graft
were passed through new tunnels beneath the ureters or
anastomosed to the incorporated limbs. Omentum was
used to cover the new graft body and as much of the limbs
as possible; if the omentum was inadequate to cover the
entire graft, the new graft limbs were tunneled via new
retroperitoneal tunnels, or we used Gerota’s fascia. Beta-
dine-soaked laparotomy sponges (10% Betadine topical
solution diluted 50% in normal saline solution) were placed
over the omentum-wrapped graft, and the intestinal defect
was repaired primarily or resected and anastomosed. Some
cases with enteric contamination required intestinal repair
to be done first. Intravenous (IV) antibiotics were admin-
istered for 4 to 8 weeks, followed by oral long-term antibi-
otic suppression. The choice of antibiotics and the durationof IV therapy were left at the discretion of the consulting
infectious disease service. Computed tomography (CT)
was done before hospital discharge. Follow-up included
clinical examination, laboratory tests (complete blood
count and serum creatine), andCT imaging every 6months
during the first year and yearly thereafter. Signs and symp-
toms of recurrent infection (fever, constitutional symp-
toms), new laboratory abnormalities (leukocytosis, ele-
vated sedimentation rate), and/or imaging findings
concerning for re-infection (perigraft fluid, fat stranding, or
abscess) prompted additional investigation and treatment.
Statistical analysis. Data were analyzed using the re-
porting standards of the Society for Vascular Surgery.21
Endpoints were morbidity and mortality, survival, re-
infection, graft patency, limb salvage, and graft-related com-
plications. Time-dependent endpoints were analyzed by
the method of Kaplan-Meier, and differences were deter-
mined by the log-rank test. Expected survival was estimated
based on the life tables from age- and gender-matched
population of the State of Minnesota. For analysis of cate-
gorical variables, the Pearson’s 2 or Fisher’s exact test was
used. Differences between means were tested with the t test
or Mann-Whitney test. A P value of less than .05 was used
to determine statistical significance. Data were presented as
median values or mean  SD, as appropriate.
RESULTS
Clinical presentation. There were 45 male patients
and 9 female patients with a mean age of 69  9 years
(Table I). Patients presented at an average of 7  5 years
(range, 0.1-22 years) after the initial operation. Symptom
Table I. Clinical characteristics of 54 consecutive
patients treated for aortic graft enteric erosion or fistula
with in situ rifampin-soaked polyester grafts
Variable n  54 Percent
Demographics
Mean age, y 69  9
Male gender 45 83
Cardiovascular risk factors
Cigarette smoking 42 78
Hypertension 40 74
Coronary artery disease 32 59
Hyperlipidemia 30 56
Peripheral arterial disease 17 31
Chronic obstructive pulmonary disease 15 28
Chronic renal insufficiency 12 22
Diabetes mellitus 9 17
Clinical presentation
Gastrointestinal bleeding 33 61
Abdominal and/or back pain 32 59
Fever 25 46
Leukocytosis 25 46
Hemorrhagic shock 10 18
Groin or flank mass 4 7
Groin sinus 3 6
Septic emboli 3 6
Leukocytosis, White blood cell count 10,000.duration average was 4 12 months. Indications for aortic
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disease in 13 patients, and both in 7 patients. Original graft
configuration was aortoiliac in 25 patients (46%), aorto-
femoral in 15 patients (28%), straight in 13 patients (24%),
and bifurcated endograft in 1 patient (2%). All patients had
symptoms at presentation, including gastrointestinal bleed-
ing in 33 patients (61%), abdominal and/or back pain in 32
patients (59%), fever in 25 patients (46%), and hemorrhagic
shock in 10 patients (21%). The average white blood cell
count was 13,500 4000 and sedimentation rate was 41
21 mm. Three patients (6%) had septic emboli to the lower
extremities.
Diagnostic studies were obtained inmost patients often
before presentation in our institution (Table II, online
only). CT of the abdomen and pelvis (Fig 4, online only)
was performed in 53 patients (98%) and had findings con-
sistent with AGEF in 49 patients (93%). Indium-labeled
white blood cell scan (In-WBC) was positive in 20 of 27
patients (75%) in whom the study was performed. The
enteric communication was confirmed in 18 of 39 patients
(46%) who underwent gastrointestinal endoscopy.
Operative treatment. A midline transperitoneal ap-
proach was used in all patients and 21 (40%) had temporary
ureteral stents (Table III). Exploration of the infected graft
revealed perigraft slime or fluid in 29 patients (54%) and
frank pus in 9 patients (17%). Forty-three patients (80%)
had partial graft infections with well-incorporated portions
of the graft body or a limb. Suprarenal or supraceliac aortic
clamp was needed in 19 patients because of supra-graft
aneurysms in 13 patients or anastomosis close to the renal
arteries in 6 patients. The left renal vein was divided in 3
patients to facilitate exposure, with subsequent reconstruc-
tion using reanastomosis in 2 patients, and interposition
graft in 1 patient because of prior ligation of venous tribu-
taries and/or renal insufficiency. Twenty-two patients
(41%) had partial graft excision with preservation of por-
tions of the iliac or femoral graft limbs. A bifurcated graft
was used in 43 patients (80%), a straight graft in 8 patients
(15%), or an isolated iliac limb in 3 patients (5%). Aorto-
femoral grafts in 8 patients were anastomosed to well-
incorporated portions of the old femoral graft limbs, avoid-
ing redo groin incisions. Repair of the intestinal defect was
performed with primary anastomosis in 46 patients and with
segmental bowel resection and anastomosis in 8 patients.
Microbiology. Blood cultures were obtained in 34
patients and were positive for organisms in 15 (44%). Aortic
graft cultures in 50 patients (Table IV, online only) were
positive for organisms in 41 patients (82%), with polymi-
crobial infections in 34 patients (85%). The most common
organisms were Streptococcus viridans in 22 patients (44%),
Candida sp in 19 (38%), Lactobacillus in 13 (26%), staphy-
lococcus coagulase-negative in 10 (20%), and Enterococcus sp
in 8 (16%). Seven of 9 patients with negative graft cultures
had received antibiotics for more than 7 days before the
operation.
Mortality and morbidity. There were five (9%) oper-
ative deaths. Operative mortality was 2.3% among patients
whowere stable at the time of their operation (1 of 44), and40% in those who had hemorrhagic shock (4 of 10; P 
.001). The death in the stable patient occurred intraoper-
atively from sudden cardiovascular collapse and cardiac
arrest not due to hemorrhage. Of the 4 patients with
hemorrhagic shock, 1 died intraoperatively, 2 from multi-
system organ failure at 1 and 81 days after operation, and
the other from disseminated intravascular coagulation the
day after ISRG replacement. Risk factors for operative
death (P  .05) on univariate analysis were hemorrhagic
shock (40% vs 2.3%), emergency operation (31% vs 0%),
female gender (22% vs 6.6%), and perigraft purulence (33%
vs 4.4%). Independent predictors (P  .01) for operative
mortality on multivariate analysis were hemorrhagic shock
(odds ratio, 16; 95% confidence interval, 3-200) and female
gender (odds ratio, 15; 95% confidence interval, 1.3-184).
Postoperative complications occurred in 28 patients
Table III. Operative data on 54 patients treated for
aortic graft enteric erosion or fistula using in situ
rifampin-soaked polyester grafts
Variable n  54 Percent
Elective operation (48 hours) 27 50
Emergency operation (6 hours) 21 39
Urgent operation (6-48 hours) 6 11
Operative findings
Partial graft body or limb infection 43 80
Total graft infection 11 20
Perigraft fluid or slime 29 54
Perigraft purulence 9 17
Supragraft anastomotic aneurysm or
pseudoaneurysm 13 24
Aortic clamp location
Infrarenal 35 65
Suprarenal 11 20
Supramesenteric or supra-celiac 8 15
Aortic replacement
Rifampin-soaked grafts 54 100
Gelatin-coated polyester grafts 37 69
Collagen-coated polyester grafts 17 31
Omental wrapping 53 98
Sartorius muscle flap coverage 2 4
Total graft replacement 31 58
Partial graft replacement 22 41
Aortoiliac 30 56
Aortofemoral 13 24
Straight 8 15
Isolated iliac or femoral graft limb 3 6
Adjuncts
Preoperative temporary ureteral stents 21 39
Cold renal perfusate 8 15
Transection/reconstruction of left renal
vein 3 6
Intestinal defect/repair
Duodenal involvement 46 85
Jejunal or ileal involvement 8 15
Primary repair 46 85
Segmental resection and anastomosis 8 15
Bowel bypass or gastrojejunostomy 5 9
Feeding or tube gastrostomy/jejunostomy 2 4
Operative time (mean  SD, hours) 6.2  1.9
Partial graft infection was defined by the presence of well-incorporated
portions of the aortic graft without any perigraft fluid or purulence.(52%; Table V). The most common complications were
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needed temporary dialysis, respiratory insufficiency in 7
patients (13%), which resulted in tracheostomy in 5 pa-
tients, and wound problems in 6 patients (11%). Early
vascular problems occurred in 5 patients, including graft
limb occlusion requiring thrombectomy in 2 patients, and
compartment syndrome, atheroembolization, and iliac vein
injury in 1 patient each. The average length of stay in the
hospital was 20  18 days. All patients completed a 4- to
8-week course of IV antibiotics, and 44 patients (90%)
received oral antibiotic suppression (Table VI, online only).
Late survival. The mean follow-up was 51 months
(range, 3-197 months). Of the 49 patients who were
available for follow-up, 46 (94%) had repeat CTs and 15
(31%) had In-WBC scans of the aortic graft. Patient survival
Table V. Early postoperative complications after in situ
aortic replacement with rifampin-soaked polyester grafts
in 54 patients with aortic graft enteric erosions or fistulas
Complication n  54 Percent
Any postoperative complication 28 52
Pulmonary complications
Respiratory insufficiency requiring
prolonged intubation 7 13
Tracheostomy 5 9
Hospital-acquired pneumonia 4 7
Renal complications
Renal insufficiency not requiring dialysis 5 9
Renal insufficiency requiring temporary
dialysis 4 7
Cardiac complications
Atrial fibrillation 3 6
Myocardial infarction 2 4
Gastrointestinal complications
Prolonged postoperative ileus 3 6
Gastrointestinal bleeding 2 4
Pancreatitis 2 4
Delayed gastric emptying 1 2
Acute acalculous cholecystitis 1 2
Clostridium difficile colitis 1 2
Enterocutaneous fistula requiring repair 1 2
Hematologic complications
Coagulopathy 2 4
Deep venous thrombosis 2 4
Disseminated intravascular coagulation 1 2
Hemolytic anemia 1 2
Wound complications
Superficial wound infection requiring
debridement 5 9
Superficial soft tissue necrosis requiring
debridement 1 2
Vascular complications
Acute graft limb occlusion requiring
thrombectomy/revision 2 4
Compartment syndrome requiring fasciotomy 1 2
Iliac vein injury 1 2
Athero-embolization to lower extremity 1 2
Total complications 68
Prolonged intubation and prolonged postoperative ileus were defined as the
need for mechanical ventilation or inability to resume enteral feeding 10
days, respectively; renal insufficiency was defined as rising creatinine 2
mg/dL or doubling of serum creatinine.at 1 year, 5 years, and 10 years was 85 5%, 59 8%, and40  9%, respectively, significantly less (P  .0001) than
age- and gender-matched controls from the general Min-
nesota population (Fig 5). Eighteen patients (37%) died
during follow-up, none from graft-related complications.
Causes of death were malignancy in 9 patients, cardiac
events in 4, pneumonia or respiratory failure in 3, and
unknown in 2.
Antibiotic suppression and graft reinfection. Forty-
four patients (90%) had antibiotic suppression, but 3
(10%) did not adhere to our recommendations to take
antibiotics. Three of 44 patients (6.8%) on oral antibiotic
suppression developed complications related to the use of
antibiotics. One patient developed peripheral neuropathy
from metronidazole, which did not improve after discon-
tinuation of the medication. Another patient developed
severe Clostridium difficile colitis from amoxicillin/clavu-
lanate, which resolved after treatment with oral metronida-
zole and vancomycin. The third patient had thrombocyto-
penia felt due to ciprofloxacin, although platelet counts
only partially improved after the antibiotic was discontin-
ued. No other complications or infections caused by
antibiotic-resistant organisms were recorded.
Graft reinfection occurred in 2 patients (4%), resulting
in freedom from graft reinfection at 10 years of 96  3%
(Fig 6). The first patient was an 87-year-old man who had
an aortofemoral ISRG with negative graft cultures, who
then developed a new 5-cm perigraft abscess 3 months later
despite antibiotic suppression with ciprofloxacin. Treat-
ment was percutaneous aspiration followed by staged
AXFB with graft removal. He had no other complications.
Culture of the infected graft grew Enterococcus sp., Lacto-
bacillus, and Candida albicans. The second patient was a
75-year-old man who underwent aortofemoral ISRG also
with negative graft cultures. The patient completed a
6-week course of IV antibiotics but received no oral anti-
biotics. He developed constitutional symptoms and peri-
graft fluid 3 months later. Fluid aspiration was negative for
organisms, but his symptoms resolved after 2 weeks of
Fig 5. Kaplan-Meier survival estimates in 54 patients treated for
aortic graft enteric erosion or fistula (AGEF) with in situ rifampin-
soaked grafts and comparison to survival of age-matched and
gender-matched controls from the Minnesota (MN) population.broad-spectrum IV antibiotics and oral antibiotic suppres-
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were no associations with risk of reinfection on univariate
analysis.
Other graft-related complications. Late graft-re-
lated complications occurred in 8 patients (16%), including
the two graft reinfections. Freedom from graft-related
complications at 1 year and 5 years was 92  3% and 81 
7%, respectively (Fig 7, online only). Of the 6 patients with
noninfectious graft-related complications, 3 developed
graft stenosis or thrombosis, treated with AXFB in 2 pa-
tients, and femoral patch angioplasty developed in 1 pa-
tient. The other 3 patients were treated for femoral anasto-
motic aneurysms. Primary graft patency at 5 and 10 years
was 92  5% and 83  10%, respectively (Fig 8, online
only). No patient required amputation.
Factors associated with increased risk (P  .05) of
graft-related complications on univariate analysis included
aortofemoral reconstruction (38% vs 7%) and coronary
artery disease (88% vs 49%). None of the variables was
independently associated with an increased risk on the
multivariable model.
DISCUSSION
Aortic graft-enteric erosions or fistulas are to be rare
but difficult surgical problems to treat. Mortality rates
reach 40% for patients with hemorrhagic or septic shock
regardless of treatment.2-4,7,13,20 Historically, one-third of
patients succumb to complications even when operations
are performed on an urgent or elective basis. Major adverse
events occur in almost two-thirds of the survivors, and
many require extended hospital or chronic care stays. The
time-honored treatment has been AXFB, graft removal,
and closure of the aortic stump.2-4 Although staging the
AXFB has improved results in contemporary series, opera-
tive mortality is as high as 27%, aortic stump blowout
remains a risk in 9%, and amputation rates are as high as
9%.3 For these reasons, a variety of treatment approaches
have evolved for aortic graft infections.
Our first report of 52 patients treated for AGEF be-
Fig 6. Kaplan-Meier estimates for freedom from graft re-
infection in 54 patients treated for aortic graft enteric erosion or
fistula (AGEF) with in situ rifampin-soaked grafts.tween 1980 and 1994, showed a 30-day mortality of 27%for the entire cohort, with death occurring in half of the
patients undergoing emergency operation and in 17% of
those who had elective repair.22 Over 80% of patients had
extra-anatomic reconstruction, but 10 patients were
treated with in situ prosthetic reconstructions because of
emergency circumstances. Overall, 9 patients treated with
AXFB required amputations, but there were no amputa-
tions among survivors of in situ reconstructions. These
outcomes prompted us to reevaluate our operative ap-
proach. Since that time, we embarked on the use of ISRG,
based on experimental and clinical evidence that indicated
efficacy of antibiotic bonding to reduce risk of graft colo-
nization and reinfection.14-20 Additionally, we routinely
covered the new graft with omentum and confined the
extent of the operation to removal of only the infected parts
of the graft.18,20 We worked under the premise that a more
limited aortic reconstruction might benefit the patient by
reducing the physiologic stress and extent of dissection
needed to excise the entire graft.
In a subsequent report from our group by Young et
al,18 which used this technique in 25 patients with aortic
graft infections of all types, the operative mortality was 8%,
no patient required amputation, and the reinfection rate
was 5%. A trend toward decreased reinfection was evident
in patients who had rifampin-soaked grafts, but the most
important factor identified with lower reinfection was a
circumferential omental wrap. Other investigators have
reported good results with ISRG in select patients with
low-grade primary aortic graft infections or infected aortic
aneurysms.14-20,23 Bandyk et al17 and the Leicester
group,19 reported re-infections in patients with ISRG
who had methicillin-resistant staphylococcus aureus (MRSA)
or rifampin-resistant Staphylococcus epidermidis strains,
suggesting that this technique be avoided in patients
with infections caused by virulent organisms.
The patients in the current study had nearly identical
presentations (hemorrhagic shock in 19% and leukocytosis
or fever in 46%) to those in our initial report from 1997.22
Although the mortality rate remains high in patients with
hemorrhagic shock (40%), outcomes improved for those
undergoing emergency operation, with a reduction in mor-
tality from 50% to 31%. Women, and those with hemor-
rhagic shock, were predictors of early mortality on multi-
variate analysis. Importantly, mortality was only 2.3% for
stable patients. Primary graft patency was 92% at 5 years,
and limb salvage was achieved in all survivors. Only 2
patients (4%) developed reinfection of the ISRG, 1 of
whom was not treated with oral antibiotic suppression, a
factor we believe important if this technique is used.
These outcomes sharply contrast to those of Armstrong
et al,4 who reported a mortality rate of 21% among 29
patients with secondary AGEF, for which the majority
(86%) was treated with AXFB and the outcomes of Valen-
tine et al24 among 38 patients, for which the mortality was
38% for graft-enteric fistulas and 36% for para-prosthetic
erosions. In the Texas Southwestern report by Valentine,
the standard approach was complete graft excision with in
situ femoral vein reconstruction in 24 patients, extra-
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Although sepsis was not an independent predictor of death
in that study, nor in ours, the percentage of patients with
fever or leukocytosis was similar in both studies (45% and
46%, respectively). These authors found duodenal leak or
colon ischemia in 10 of 38 patients, which resulted in death
in 9 patients. Gastrointestinal complications were identified
as an independent predictor for death. The authors appro-
priately suggest that duodenal closure could be a crucial
determinate of outcome, although simple closure was used
in 26 of 30 cases that involved the duodenum. The inci-
dence of colon ischemia in that report highlights the im-
portance of preservation of pelvic circulation and a careful
assessment of visceral artery disease before operation. Al-
though colon ischemia may be unavoidable in some pa-
tients, we believe that more extensive dissection to achieve
total graft excision could disrupt collateral blood supply.
Clearly, the use of ISRG as described in our report is
best reserved for patients with limited graft contamination
and not in those with large abscesses or excessive purulence.
For the latter patients, a variety of options exists. Staged
AXFB in a stable patient may limit the physiologic stress
compared to simultaneous extra-anatomic bypass and graft
resection.3-4 In these cases, we prefer a three-layer aortic
stump closure with omental coverage. Alternatively, a neo-
aortoiliac system using femoral vein, as espoused by Clagett
et al5 and Nevelsteen et al6 is the best option for prevention
of reinfection. The neo-aortoiliac system is ideal in stable
patients with excessive purulence, groin abscesses, or viru-
lent organisms such as MRSA, Pseudomonas aeruginosa,
and other rifampin-resistant strains.5-9 In a report of 187
patients treated for aortic graft infections of any cause, these
authors noted procedure-related mortality to be 14%, ma-
jor amputation 7%, and graft disruption 5%.7 Although
fasciotomy was needed in 21% of the patients when the vein
was harvested below the adductor hiatus, long-term venous
sequela was uncommon.7-9
Cryopreserved arterial allografts may also be used in the
aforementioned circumstances but may not be available for
emergency operations. Moreover, these grafts are expen-
sive.10-13 The use of arterial allografts was fueled by the
good results achieved with valve homografts and treatment
of mycotic aneurysms.10-13 Kieffer et al13 reported on 172
patients treated for aortic graft infection with this tech-
nique, including 54 with AGEF. In that study, mortality
was 20%, with higher rates for emergency operations and
patients with AGEF or septic shock. Six (4%) early deaths
were caused by allograft rupture, all in patients with AGEF.
The US Cryopreserved Allograft Registry found the allo-
graft rupture and early graft thrombosis rates to be 9%.12
Graft deterioration may be immune-mediated, mechanical,
or associated with reinfection, but regardless of the mech-
anism, these results raise concern about the integrity of
these conduits in infected fields.
Endovascular approach potentially is a less invasive
alternative for treatment. One advantage is the ability to
rapidly control hemorrhage, which avoids the need to open
a hostile abdomen. This is thought to decrease trauma,physiologic stress, and the potential complications of redo
aortic operations. However, stent grafts fail to address the
enteric communication, which remains a nidus for bacterial
growth and infection. Successful early results have been
tempered by reports with larger experiences and longer
follow-up.25 A systematic review of 33 reports by Antoniou
et al25 included 44 patients treated with stent grafts, 43% of
whom had primary graft erosions and 44% with aortic-
esophageal fistulas. Persistent or recurrent infection oc-
curred in 44% of patients after an average follow-up of 1
year, which resulted in significantly more complications,
higher 30-day mortality rates (17% vs 0%), and decreased
long-term survival, which was only 40% at 2 years. More-
over, the use of stent grafts implies aortic neck anatomy
sufficient for coverage of the enteric communication. In
our study, one-third of patients had unsuitable aortic necks
because of proximity to the renal arteries or supragraft
aneurysm (Fig 3, online only). Endovascular techniques
may have a role as a “bridge” to open repair for select
patients with hemorrhagic shock, because the mortality in
this subset is high regardless of treatment.
Several shortcomings of our study deserve comment. A
number of factors involved in decision making may have
been missed because of the retrospective design. Because
several patients were transferred over long distances for
care, there may be a selection bias toward more stable
patients, which may differ from other tertiary medical cen-
ters in metropolitan areas. Nonetheless, the strength of our
study relies on a relatively large number of patients treated
with a uniform approach over the last 18 years.
In conclusion, treatment of AGEF in our institution
has evolved from extra-anatomic reconstruction to ISRG
with omental coverage and oral antibiotic suppression in
87% of patients treated since 1990. ISRG replacement
should be avoided in patients with large abscess or perigraft
purulence. However, ISRG is an expeditious option for
aortic reconstruction in the unstable patient, has a low
mortality rate in stable patients (2.3%), and excellent limb
salvage and graft reinfection rates (4%).
The authors would like to thank the vascular surgeons,
past and present, who were involved in the care of these
patients at the Mayo Clinic, and Mr Michael King for
preparation of medical illustrations.
AUTHOR CONTRIBUTIONS
Conception and design: GO
Analysis and interpretation: GO, TB, JH, MK, AD, JW,
SC, PG
Data collection: GO, JH
Writing the article: GO, TB, JH, MK, AD, JW, SC, PG
Critical revision of the article: GO, TB, JH, MK, AD, JW,
SC, PG
Final approval of the article: GO, TB, JH, MK, AD, JW,
SC, PG
Statistical analysis: GO, SC
Obtained funding: GO
Overall responsibility: GO
JOURNAL OF VASCULAR SURGERY
January 2011106 Oderich et alREFERENCES
1. Hallett JW Jr, Marshall DM, Petterson TM, Gray DT, Bower TC,
Cherry KJ Jr, et al. Graft-related complications after abdominal aortic
aneurysm repair: reassurance from a 36-year population-based experi-
ence. J Vasc Surg 1997;25:277-84; discussion 285-6.
2. Reilly LM, Stoney RJ, Goldstone J, Ehrenfeld WK. Improved manage-
ment of aortic graft infection: the influence of operation sequence and
staging. J Vasc Surg 1987;5:421-31.
3. Kuestner LM, Reilly LM, Jicha DL, EhrenfeldWK, Goldstone J, Stoney
RJ. Secondary aortoenteric fistula: contemporary outcome with use of
extraanatomic bypass and infected graft excision. J Vasc Surg 1995;21:
184-95; discussion 195-6.
4. Armstrong PA, Back MR, Wilson JS, Shames ML, Johnson BL, Bandyk
DF. Improved outcomes in the recent management of secondary aor-
toenteric fistula. J Vasc Surg 2005;42:660-6.
5. Clagett GP, Bowers BL, Lopez-Viego MA, Rossi MB, Valentine RJ,
Myers SI, Chervu A. Creation of a neo-aortoiliac system from lower
extremity deep and superficial veins. Ann Surg 1993;218:239-48; dis-
cussion 248-9.
6. Nevelsteen A, Lacroix H, Suy R. Autogenous reconstruction with the
lower extremity deep veins: an alternative treatment of prosthetic infec-
tion after reconstructive surgery for aortoiliac disease. J Vasc Surg
1995;22:129-34.
7. Ali AT, Modrall JG, Hocking J, Valentine RJ, Spencer H, Eidt JF,
Clagett GP. Long-term results of the treatment of aortic graft infections
by in situ replacement with femoral popliteal vein grafts. J Vasc Surg
2009;50:30-9.
8. Modrall JG, Sadjadi J, Ali AT, Anthony T, Welborn MB 3rd, Valentine
RJ, et al. Deep vein harvest: predicting need for fasciotomy. J Vasc Surg
2004;39:387-94.
9. Wells JK, Hagino RT, Bargmann KM, Jackson MR, Valentine RJ,
Kakish HB, Clagett GP. Venous morbidity after superficial femoral-
popliteal vein harvest. J Vasc Surg 1999;29:282-9; discussion 289-91.
10. Chiesa R, Astore D, Piccolo G, Melissano G, Jannello A, Frigerio D, et
al. Fresh and cryopreserved arterial homografts in the treatment of
prosthetic graft infections: experience of the Italian Collaborative Vas-
cular Homograft Group. Ann Vasc Surg 1998;12:457-62.
11. Verhelst R, Lacroix V, Vraux H, Lavigne JP, VandammeH, Limet R, et
al. Use of cryopreserved arterial homografts for management of infected
prosthetic grafts: a multicentric study. Ann Vasc Surg 2000;14:602-7.
12. Noel AA, Gloviczki P, Cherry KJ Jr, Safi H, Goldstone J, MoraschMD,
Johansen KH. Abdominal aortic reconstruction in infected fields: early
results of theUnited States cryopreserved aortic allograft registry. J Vasc
Surg 2002;35:847-52.
13. Kieffer E, Gomes D, Chiche L, Fléron MH, Koskas F, Bahnini A.
Allograft replacement for infrarenal aortic graft infection: early and late
results in 179 patients. J Vasc Surg 2004;39:1009-17.
teal vein grafts. The latter option is ideal in the stable patient with14. WalkerWE, CooleyDA,Duncan JM,HallmanGL Jr, Ott DA, Reul GJ.
The management of aortoduodenal fistula by in situ replacement of the
infrarenal abdominal aortic graft. Ann Surg 1987;205:727-32.
15. Colburn MD, Moore WS, Chvapil M, Gelabert HA, Quiñones-
Baldrich WJ. Use of an antibiotic-bonded graft for in situ reconstruc-
tion after prosthetic graft infections. J Vasc Surg 1992;16:651-8; dis-
cussion 658-60.
16. Strachan CJ, Newsom SW, Ashton TR. The clinical use of an antibiotic-
bonded graft. Eur J Vasc Surg 1991;5:627-32.
17. Bandyk DF, Novotney ML, Johnson BL, Back MR, Roth SR. Use of
rifampin-soaked gelatin-sealed polyester grafts for in situ treatment of
primary aortic and vascular prosthetic infections. J Surg Res 2001;95:
44-9.
18. Young RM, Cherry KJ Jr, Davis PM, Gloviczki P, Bower TC, Panneton
JM, Hallett JW Jr. The results of in situ prosthetic replacement for
infected aortic grafts. Am J Surg 1999;178:136-40.
19. Hayes PD, Nasim A, London NJ, Sayers RD, Barrie WW, Bell PR,
Naylor AR. In situ replacement of infected aortic grafts with rifampicin-
bonded prostheses: the Leicester experience (1992 to 1998). J Vasc
Surg 1999;30:92-8.
20. Oderich GS, Bower TC, Cherry KJ Jr, Panneton JM, Sullivan TM,Noel
AA, et al. Evolution from axillofemoral to in situ prosthetic reconstruc-
tion for the treatment of aortic graft infections at a single center. J Vasc
Surg 2006;43:1166-74.
21. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S,
Jones DN. Recommended standards for reports dealing with lower
extremity ischemia: revised version. J Vasc Surg 1997;26:517-38.
22. Menawat SS, Gloviczki P, Serry RD, Cherry KJ, Bower TC, Hallett JW
Jr. Management of aortic graft-enteric fistulae. Eur J Vasc Endovasc
Surg 1997;14 Suppl A:74-81.
23. Oderich GS, Panneton JM, Bower TC, Cherry KJ Jr, Rowland CM,
Noel AA, et al. Infected aortic aneurysms: aggressive presentation,
complicated early outcome, but durable results. J Vasc Surg 2001;34:
900-8.
24. Valentine RJ, Timaran CH, Modrall GJ, Smith ST, Arko FR, Clagett
GP. Secondary aortoenteric fistulas versus paraprosthetic erosions: is
bleeding associated with a worse outcome? J Am Coll Surg 2008;207:
922-7.
25. AntoniouGA, Koutsias S, Antoniou SA, Georgiakakis A, LazaridesMK,
Giannoukas AD. Outcome after endovascular stent graft repair of
aortoenteric fistula: a systematic review. J Vasc Surg 2009;49:782-9.
Submitted Jun 17, 2010; accepted Aug 6, 2010.
Additional material for this article may be found online
at www.jvascsurg.org.DISCUSSION
Dr Anton Sidawy (Washington, DC). You presented three
ways to take care of infected grafts, how do you decide in your
practice which method to use? In situ rifampin-soaked grafts, in
situ femoropopliteal grafts, or whether you do an extra-anatomic
bypass? Is it the preference of the surgeon?
Dr Oderich. No, surgeon preference did not affect our man-
agement, which is evident by the use of in situ rifampin grafts in
nearly 90% of patients. We have a uniform approach at the Mayo
Clinic, and Dr Hallett, who is waiting to ask his question, can
perhaps comment on that later.
Aortic graft enteric erosions are different compared to primary
graft infections; type of organism, involvement of the graft, and
risk of reinfection is totally different. The vast majority of patients
with graft-enteric erosions are treated with a rifampin graft, except
for the minority (10%) who have a large abscess on preoperative
CT scan or excessive perigraft purulence on exploration. For those,
we use either a staged axillofemoral bypass or in situ femoropopli-primary graft infection and purulence, involvement of the groin, or
a virulent organism.
However, I would like to emphasize that the vast majority of
patients with graft enteric erosion, at least in our practice, have a
partial process that is localized to the main body or to a portion of
the graft limb, and oftentimes there are portions of the graft that
are well incorporated and can be preserved, which minimize the
operation.
Dr John Jeb Hallett (Charleston, SC). I rise to congratulate
you on following up on these challenging patients. Historical
credit should be given to Dr Denton Cooley and his surgeons who
really presented this idea back in the 1980s, and it was from their
ideas that we began to use the in situ techniques and rifampin at the
Mayo Clinic. At the time, in situ management of aortic graft
infections was heresy. Therefore, it is gratifying to hear your report
today of excellent and durable results.
I have one question: Is there something special about rifampin
that some other antibiotic does not offer?
JOURNAL OF VASCULAR SURGERY
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Indeed, the credit is to the Texas-Houston group and this is
acknowledged in the manuscript. Rifampin is one of the antibiotics
that has been studied and has excellent bonding to polyester grafts.
The intent initially was to prevent low-grade infections caused by
staph epidermidis and staph aureus. It does have excellent coverage
for some of the other gram-positive organisms such as streptococcus
viridans and intermediate coverage to some of the gram-negative
organisms. Recently, clinical use of rifampin grafts has been broad-
ened to other types of infections, but probably rifampin is not the
main factor that decreased reinfection rates in our study. I think it
is the whole package of the patient selection, the use of rifampin,
the omental wrapping, the debridement, and the use of postoper-
ative oral antibiotics that accounts for these outcomes. Omental
wrapping is a key factor and was demonstrated previously to reduce
reinfections.
Dr William Quinones-Baldrich (Los Angeles, Calif). In the
report of your prior experience with treatment of aortoenteric
erosion and fistulas, you had a recurrence rate of 3%. The recur-
rence rate reported today was 4%. You are performing a number of
other maneuvers that are intended to reduce the recurrence rate.
There is nothing wrong with soaking the graft in rifampin, but the
question remains: Does rifampin really make a difference?
Dr Oderich.Well, the only way to would be to do a prospec-
tive study, which is not possible with this disease.
Based on experimental studies and clinical experience, ri-
fampin does add by decreasing the chance of the graft of being
colonized or infected. That has been tested for other organisms or
in experimental studies, it has not been tested for other gram-
negative organisms or streptococcus. Therefore, we do not know the
definitive answer of that. We do continue to use this protocol, but
we believe that other factors such as patient selection, debride-
ment, omental wrapping, and IV and oral antibiotics are very
important for good results.
Dr K. Wayne Johnston (Toronto, Ontario, Canada). Differ-
ent manufacturers coat their grafts with different materials. Am Icorrect that rifampin binds most effectively to one graft type rather
than another?
Dr Oderich. The two grafts that were tested most were
collagen-impregnated or gelatin-impregnated grafts. Both bind
rifampin effectively on experimental studies. Some investigators
postulate that collagen grafts may denature the rifampin and
decrease the antibacterial activity.
The selection of the type of graft has not affected the outcome
in our study. This selection was based on surgeon preference in our
practice with a distribution of 70% gelatin and 30% collagen.
Dr Robert Rhee (Pittsburgh, Pa). These results are encour-
aging, and I was wondering if you have had any experience with
graft infections or aorto-esophageal fistulas involving the thoraco-
abdominal aorta? In other words, in situations in which you do not
really have a choice except to do an in-line reconstruction?
Dr Oderich. We have treated aortoesophageal fistulas after
thoracic stent grafts with a rifampin-soaked graft, but the experi-
ence is small to make recommendations. One factor is coverage of
the graft with omentum, which can be challenging albeit possible
in the chest.
Dr Richard Cambria (Boston, Mass). We have done about 30
of these. In addition, although we do not have the numbers or the
duration of follow-up, we do not know of a case of reinfection. In
addition, particularly the way that you selected your patients and
you pointed out that frequently the infection is localized, this
ought to work.
My question is: Have you used it in native infected aneurysms?
Because we have in selected cases as well.
DrOderich. Thank you for your comments, Dr Cambria. We
have used this in mycotic aneurysms. Actually, I recently did a case
of a perivisceral mycotic aneurysm using this technique. Moreover,
the reinfection rate for mycotic aneurysms was low at 4% in a
previous series that we published 10 years ago. Of course, patients
that have virulent organisms, such as MRSA, pseudomonas aerugi-
nosa are best suited for other types of reconstruction such as
femoral vein graft.
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January 2011107.e1 Oderich et alFig 2 (online only). A 60-year-old male with prior e
presented with fever, leukocytosis, and abdominal pain.
aneurysm sac, lack of fat plane between the duodenum
percutaneous drainage of the abscess cavity, the endogra
femoropopliteal vein graft (C and D).ndovascular repair of infrarenal abdominal aortic aneurysm
A, A computed tomography angiography revealed air in the
and aneurysm sac, and large left psoas muscle abscess. After
ft was explanted (B) and the aorta was replaced in situ using-
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Volume 53, Number 1 Oderich et al 107.e2Fig 3 (online only). A, A 68-year-old male treated for aortic graft enteric fistula with an in situ rifampin-soaked graft.
B, Portion of the infected graft and aortic wall were left attached to the duodenal defect, showing the anastomotic line
involved by fistula. C, The illustration depicts a “fishmouth” anastomosis, which was used in patients with supra-graft
aneurysms or anastomosis close to the renal arteries. D, Follow-up computed tomography angiography revealed a
well-incorporated main graft body and iliac limbs without evidence of reinfection.Table II (online only). Diagnostic studies and positive
yield in 54 consecutive patients treated for aortic graft
enteric erosion or fistula with in situ rifampin-soaked
polyester grafts
Diagnostic study n  54 Percent
Result
Positive Negative
n (Percent)
Computed tomography
scan 53 98 49 (93) 4 (7)
Upper endoscopy 39 72 18 (46) 21 (54)
In-WBC scan 27 50 20 (75) 7 (25)
Conventional
angiography 17 31 6 (35) 11 (65)In-WBC scan, Indium-labeled white blood cell scan.
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January 2011107.e3 Oderich et alFig 4 (online only). Computed tomography of the abdomen and intraoperative photographs in 3 patients with aortic
graft enteric erosion or fistulas. Findings included evidence of a portion of the graft within the lumen of the jejunum
(small arrow) as shown in a patient with prior stenting of the graft limb (A); note the well-incorporatedmain graft body
(curved arrow). Other findings included lack of fat plane between the graft and bowel and/or presence of perigraft air
and fluid (B, small arrow) and supra-graft para-anastomotic aneurysm (C, arrowhead) associated with lack of fat plane
between the graft and bowel in a patient with aortic graft fistula with involvement of the anastomotic suture line (C,
long arrow).
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aortic graft and periaortic tissue cultures
Aortic graft or aortic/periaortic wall tissue n  50 Percent
Positive culture 41 82
Negative culturea 9 18
Polymicrobial 34 68
Monomicrobial 6 12
Gram-negative organism 33 66
Gram-positive organism 28 56
Fungi 21 42
Anaerobes 19 38
Microorganism
Streptococcus viridans 22 44
Candida sp 19 38
Lactobacillus 13 26
Staphylococcus coagulase negative 10 20
Enterococcus 8 16
Escherichia coli 7 12
Bacteriodes fragilis 5 10
Klebsiella sp 5 10
Prevotella sp 4 8
Enterobacter cloacae 3 6
Staphylococcus aureus 2 4
Proteus mirabilis 2 4
Eikenella corrodens 2 4
Corynebacterium sp 2 4
Rothia mucilaginosa 1 2
Pseudomonas aeruginosa 1 2
Peptostreptococcus 1 2
Nocardia 1 2
Citrobacter freundii 1 2
Campylobacter 2 2
aSeven of 9 patients had antibiotic therapy for 7 days before their opera-
tion.
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aortic graft enteric erosions or fistulas
Antibiotic Dose Selected adverse effects
No antibiotic suppression
Antibiotic suppression
Sulfamethoxazole/trimethoprim 400-800 mg/80-160 mg PO qd Rash, nausea/vomiting, bone marrow suppression,
Stevens-Johnson syndrome
Fluconazole 400-800 mg PO qd GI effects, increased liver enzymes, headache,
Stevens-Johnson syndrome, anaphylaxis
Amoxicillin/clavulanate 875 mg/125 mg PO qd or bid Rash, nausea/vomiting, diarrhea, anaphylaxis, C
difficile colitis, thrombocytopenia, hepatitis
Metronidazole 250-500 mg PO qd Nausea, diarrhea, disulfiram-like reactions to
alcohol, peripheral neuropathy, neutropenia
Ciprofloxacin 500 mg PO bid GI effects, restlessness, Stevens-Johnson syndrome,
neutropenia, thrombocytopenia, neuropathy
Levofloxacin 250-500 mg PO qd GI effects, prolonged QT interval, Stevens-
Johnson syndrome, aplastic anemia, seizure,
renal failure
Cephalexin 250-500 mg PO qd GI effects, hypersensitivity, C difficile colitis
Moxifloxacin 400 mg po qd GI effects, prolonged QT interval, Stevens-
Johnson syndrome, agranulocytosis
Itraconazole 200 mg PO qd Rash, hypokalemia, diarrhea, congestive heart
failure, Stevens-Johnson syndrome, neutropenia
Pen V 250-500 mg PO qd-bid Hypersensitivity, GI effects, hemolytic anemia
Linezolid 600 mg PO bid Rash, GI effects, headache, fever, lactic acidosis,
myelosuppression, peripheral neuropathy
Antibiotic combinations
First medication Second medication
Sulfamethoxazole/trimethoprim
Amoxicillin/clavulanate
Ciprofloxacin
Sulfamethoxazole/trimethoprim Fluconazole
Amoxicillin/clavulanate Fluconazole
Sulfamethoxazole/trimethoprim Amoxicillin/clavulanate
Metronidazole
Levofloxacin Metronidazole
Cephalexin alone
Cephalexin Fluconazole
Cephalexin Metronidazole
Levofloxacin
Moxifloxacin Fluconazole
Moxifloxacin
Itraconazole
Linezolid Fluconazole
Penicillin VPO, Prescribed orally; qd, every day; GI, gastrointestinal.
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Spectrum Target organism n  49 Percent
— 5 10
44 90
Gram-negative bacilli, Gram-positive coccus E. coli, Haemophilus influenza, Klebsiella, Enterobacter, Citrobacter
freundii, Staphylococcus, P mirabilis, Nocardia
17 35
Fungi Candida albicans, Candida tropicalis, Candida parapsilosis,
Candida unspeciated
12 24
Gram-negative bacilli, Gram-positive coccus E. coli, Haemophilus influenza, Nocardia, Peptostreptococcus sp, P
mirabilis, Staphylococcus, Streptococcus viridans, Enterobacter sp,
Citrobacter
11 22
Anaerobes Bacteriodes fragilis, Clostridium sp, C difficile 5 10
Gram-negative bacilli, Gram-positive coccus,
Gram-positive bacilli
Bacillus sp, Campylobacter, Citrobacter freundii, Enterobacter sp, E.
coli, Haemophilus influenza, Klebsiella pneumoniae, Pseudomonas
aeruginosa
5 10
Gram-negative bacilli, Gram-positive coccus,
Gram-positive bacilli
Bacillus sp, Campylobacter, Citrobacter freundii, Enterobacter sp, E.
coli, Haemophilus influenza, Klebsiella pneumoniae, Pseudomonas
aeruginosa
3 6
Gram-negative bacilli and Gram-positive
coccus
E. coli, Peptostreptococcus sp, P mirabilis, Staphylococcus,
Streptococcus viridans
3 6
Gram-negative bacilli, Gram-positive coccus,
Gram-positive bacilli
Bacillus sp, Campylobacter, Citrobacter freundii, Enterobacter sp, E.
coli, Haemophilus influenza, Klebsiella pneumoniae, Pseudomonas
aeruginosa
2 4
Fungi Candida glabrata, Candida krusei 1 2
Gram-positive coccus Streptococcus viridans 1 2
Enterococci resistant to vancomycin (VRE) 1 2
n %
11 22
6 12
4 8
4 8
3 6
2 4
2 4
2 4
1 2
1 2
1 2
1 2
1 2
1 2
1 2
1 2
1 2
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January 2011107.e7 Oderich et alFig 7. (online only). Kaplan-Meier estimates for freedom from
graft-related complications in 54 patients treated for aortic graft
enteric erosion or fistula (AGEF) with in situ rifampin-soaked
grafts. The dotted line represents an SD  10%.Fig 8. (online only). Kaplan-Meier estimates for primary graft
patency in 54 patients treated for aortic graft enteric erosion or
fistula (AGEF) with in situ rifampin-soaked grafts.
